文献速递肥胖与代谢综合征糖尿病

减重手术后炎症小体机制组分的失调:慢性疾病的新靶点

Dysregulation of Components of the Inflammasome Machinery After Bariatric Surgery: Novel Targets for a Chronic Disease.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

发现术后炎症小体组分(尤其NLRs及细胞周期/DNA损伤调节因子)显著失调,部分组分与基线代谢合并症(如2型糖尿病)相关,且多数变化不依赖术式。

要点

  • 减重术后外周血单核细胞炎症小体组分基因表达谱发生显著改变。
  • 部分炎症小体组分表达与基线2型糖尿病、高血压、血脂异常相关。
  • 多数术后变化不依赖于所采用的减重手术方式。

核心结论

  • 减重手术诱导外周血单核细胞炎症小体机制组分基因表达模式的深刻改变。
  • 某些炎症小体组分的表达及变化与基线代谢合并症(包括2型糖尿病)相关,可能与术后肥胖相关合并症的改善和逆转有关。

研究设计与样本

  • 在基线和术后6个月进行流行病学/临床/人体测量/生化评估,并检测外周血单核细胞中炎症小体组分及炎症相关因子。
  • 在肝HepG2细胞中分析特定炎症小体组分沉默后的功能参数(脂质积累/活力/凋亡)。

主要发现

  • 减重术后炎症小体组分出现 profound 失调,尤其NLRs和细胞周期及DNA损伤调节因子。
  • 基线代谢合并症与特定组分相关:2型糖尿病与CCL2/CXCR1/SIRT1相关;高血压与AIM2/ASC/P2X7相关;血脂异常与CXCL3/NLRP7相关。
  • 某些因子(NLRC4/NLRP12/CXCL3/CCL8/TLR4)的基因表达指纹能准确区分术前和术后PBMCs。
  • 大多数变化不依赖于所施行的手术技术。
  • 沉默NLRC4/NLRP12导致HepG2细胞脂质积累、凋亡率和细胞活力改变。

临床怎么用

  • 减重术后炎症小体组分的变化可能作为监测代谢合并症改善的生物标志物。
  • 特定炎症小体组分(如NLRC4/NLRP12)可能成为肥胖相关慢性疾病的治疗靶点。

局限性

  • 仅评估术后6个月的变化,缺乏长期随访数据。
  • 机制研究主要在HepG2细胞中进行,体内功能验证有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Obesity is a metabolic chronic disease with important associated morbidities and mortality. Bariatric surgery is the most effective treatment for maintaining long-term weight loss in severe obesity and, consequently, for decreasing obesity-related complications, including chronic inflammation. AIM: To explore changes in components of the inflammasome machinery after bariatric surgery and their relation with clinical/biochemical parameters at baseline and 6 months after bariatric surgery. PATIENTS AND METHODS: Twenty-two patients with morbid-obesity that underwent bariatric surgery (sleeve gastrectomy and Roux-en-Y gastric bypass) were included. Epidemiological/clinical/anthropometric/biochemical evaluation was performed at baseline and 6 months after bariatric surgery. Inflammasome components and inflammatory-associated factors [nucleotide-binding oligomerization domain-like receptors (NLRs), inflammasome activation components, cytokines and inflammation/apoptosis-related components, and cell-cycle and DNA-damage regulators) were evaluated in peripheral blood mononuclear cells (PBMCs) at baseline and 6 months after bariatric surgery. Clinical molecular correlations/associations were analyzed. Functional parameters (lipid accumulation/viability/apoptosis) were analyzed in response to specific inflammasome components silencing in liver HepG2 cells). RESULTS: A profound dysregulation of inflammasome components after bariatric surgery was found, especially in NLRs and cell-cycle and DNA damage regulators. Several components were associated with baseline metabolic comorbidities including type 2 diabetes (C-C motif chemokine ligand 2/C-X-C motif chemokine receptor 1/sirtuin 1), hypertension (absent in melanoma 2/ASC/purinergic receptor P2X 7), and dyslipidemia [C-X-C motif chemokine ligand 3 (CXCL3)/NLR family pyrin domain containing (NLRP) 7) and displayed changes in their molecular profile 6 months after bariatric surgery. The gene expression fingerprint of certain factors NLR family CARD domain containing 4 (NLRC4)/NLRP12/CXCL3)/C-C motif chemokine ligand 8/toll-like receptor 4) accurately differentiated pre- and postoperative PBMCs. Most changes were independent of the performed surgical technique. Silencing of NLRC4/NLRP12 resulted in altered lipid accumulation, apoptosis rate, and cell viability in HepG2 cells. CONCLUSION: Bariatric surgery induces a profound alteration in the gene expression pattern of components of the inflammasome machinery in PBMCs. Expression and changes of certain inflammasome components are associated to baseline metabolic comorbidities, including type 2 diabetes, and may be related to the improvement and reversion of some obesity-related comorbidities after bariatric surgery.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Herrero-Aguayo V, Sáez-Martínez P, López-Cánovas JL, et al. Dysregulation of Components of the Inflammasome Machinery After Bariatric Surgery: Novel Targets for a Chronic Disease. J Clin Endocrinol Metab. 2021. PMID: 34363480. doi:10.1210/clinem/dgab586

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。